A study of blood coagulation was made on cardiac patients with and without acute myocardial infarction, prior to anticoagulant therapy. The heparin clotting time, an in vitro modification of the heparin tolerance test, was accelerated in 74 per cent (14 out of 19) of the patients with acute myocardial infarction studied within three weeks after the attack. One out of 14 patients without acute myocardial infarction had an accelerated heparin clotting time below 20 minutes, the lower limit of the "normal" range established on the basis of study of over 100 control subjects. The clotting time and platelet count revealed no significant variations. Serial coagulation studies, performed on patients receiving Dicumarol therapy, revealed that the heparin clotting time, which provides a sensitive measure of over-all coagulability, is prolonged as the prothrombin concentration is diminished. The significance of these findings in relation to thromboembolic complications of acute myocardial infarction and anticoagulant therapy is discussed. 
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INVESTIGATION OF the basic abnormali-
ties of the clotting mechanism in thromboembolic diseases has been summarized in 
:E.R. were performed on a group of patients during Dicumarol therapy for acute myocardial infarction. Blood was drawn with a dry syringe and a 20 gage needle. Care was exercised to avoid trauma in order to minimize contamination with tissue juice. The first and last cubic centimeter of blood in the syringe were discarded. The following tests were done: clotting time, heparin clotting time, platelet count and hematocrit. The clotting time and heparin clotting time were done according to methods described in a previous report.4 In essence, both tests were performed in a water bath set at 37 C., and the end point of clotting was timed from the appearance of the blood in the syringe to In the present study, no increase in platelet count occurred in conjunction with the accelerated clotting. However, this does not exclude the possibility of qualitative changes in platelets, such as in adhesive and agglutination properties, as factors in the increased coagulability. The amount of thromboplastin and its precursors in the blood is probably of great importance in all thromboembolic diseases, but the exact nature of thromboplastin is obscure and subject to controversy. Deficiency of normal circulating clotting inhibitors such as antithrombin or endogenous heparin derived from the mast cells may account for the rapid coagulability. Whatever its significance and mechanism, it appears that the increased coagulability of the blood in acute myocardial infarction portends a threat of thrombo-embolization and is further indication of the importance of anticoagulant therapy to decrease the clotting tendency.
This study indicates that the heparin clotting time is markedly altered following Dicumarol therapy. As the prothrombin concentration decreases, the heparin clotting time increases. Recent reports have emphasized the need for accurate and frequent checks of the prothrombin time in order to avoid hemorrhagic complications during Dicumarol therapy. ' 14 patients with cardiovascular disease but without acute myocardial infarction simultaneously studied had a rapid heparin clotting time. The clotting times and platelet counts were normal in both groups of patients.
The significance of this hypercoagulability in acute myocardial infarction in relation to thrombo-embolic complications and additional rationale in favor of anticoagulant therapy is discussed.
Dicumarol therapy was found to have a marked effect in prolonging the heparin clotting time which provides a sensitive measure of over-all coagulability and, hence, may be a valuable test in the control of anticoagulant therapy. Whether the heparin clotting time follows the prothrombin activity or other clotting indexes closely enough to be the sole guide for therapy with the coumarin derivatives and phenylindandione must await further investigation and experience.
